# IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

> **NCT06940440** · PHASE1 · RECRUITING · sponsor: **TuHURA Biosciences, Inc.** · enrollment: 9 (estimated)

## Conditions studied

- Advanced Or Metastatic Merkel Cell Carcinoma

## Interventions

- **DRUG:** IFx-Hu2.0
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06940440
- **Lead sponsor:** TuHURA Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2026-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940440, "IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06940440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*